Literature DB >> 19047281

Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

Shaheenah Dawood1, Kristine Broglio, Shu-Wan Kau, Marjorie C Green, Sharon H Giordano, Funda Meric-Bernstam, Thomas A Buchholz, Constance Albarracin, Wei T Yang, Bryan T J Hennessy, Gabriel N Hortobagyi, Ana Maria Gonzalez-Angulo.   

Abstract

PURPOSE: The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers. PATIENTS AND METHODS: Four hundred seventy-one patients with TN breast cancer diagnosed between 1996 and 2005 and treated with primary systemic chemotherapy were included. pCR was defined as no residual invasive cancer in the breast and axillary lymph nodes. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier product-limit method and compared between groups using the log-rank test. Cox proportional hazards models were fitted for each survival outcome to determine the relationship of patient and tumor variables with outcome.
RESULTS: Median follow-up time was 24.5 months. One hundred patients (21.2%) were black, and 371 patients (78.8%) were white/other race. Seventeen percent of black patients (n = 17) and 25.1% of white/other patients (n = 93) achieved a pCR (P = .091). Three-year RFS rates were 68% (95% CI, 56% to 76%) and 62% (95% CI, 57% to 67%) for black and white/other patients, respectively, with no significant difference observed between the two groups (P = .302). Three-year OS was similar for the two racial groups. After controlling for patient and tumor characteristics, race was not significantly associated with RFS (hazard ratio [HR] = 1.08; 95% CI, 0.69 to 1.68; P = .747) or OS (HR = 1.08; 95% CI, 0.69 to 1.68; P = .735) when white/other patients were compared with black patients.
CONCLUSION: Race does not significantly affect pCR rates or survival outcomes in women with TN breast cancer treated in a single institution under the same treatment conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047281      PMCID: PMC4516695          DOI: 10.1200/JCO.2008.17.9952

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Black/white differences in type of initial breast cancer treatment and implications for survival.

Authors:  W P McWhorter; W J Mayer
Journal:  Am J Public Health       Date:  1987-12       Impact factor: 9.308

2.  The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization.

Authors: 
Journal:  Am J Clin Pathol       Date:  1982-12       Impact factor: 2.493

3.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

4.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

5.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

9.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

Authors:  Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment.

Authors:  Kenneth C Chu; Charisee A Lamar; Harold P Freeman
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

View more
  45 in total

1.  African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.

Authors:  Ani Balmanoukian; Zhe Zhang; Stacie Jeter; Shannon Slater; Deborah K Armstrong; Leisha A Emens; John H Fetting; Antonio C Wolff; Nancy E Davidson; Lisa Jacobs; Julie Lange; Theodore N Tsangaris; Richard Zellars; Edward Gabrielson; Vered Stearns
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

Review 2.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Authors:  Abenaa M Brewster; Mariana Chavez-MacGregor; Powel Brown
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

3.  Nomogram for predicting survival in triple-negative breast cancer patients with histology of infiltrating duct carcinoma: a population-based study.

Authors:  Dongjun Dai; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.

Authors:  J R Tichy; A M Deal; C K Anders; K Reeder-Hayes; L A Carey
Journal:  Breast Cancer Res Treat       Date:  2015-03-27       Impact factor: 4.872

Review 5.  Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.

Authors:  Eric C Dietze; Tanya A Chavez; Victoria L Seewaldt
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

Review 6.  Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups.

Authors:  Tejal A Patel; Gerardo Colon-Otero; Celyne Bueno Hume; John A Copland; Edith A Perez
Journal:  Oncologist       Date:  2010-04-28

7.  Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.

Authors:  Lisa D Volk-Draper; Sandeep Rajput; Kelly L Hall; Andrew Wilber; Sophia Ran
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Does race affect outcomes in triple negative breast cancer?

Authors:  Jasgit C Sachdev; Saira Ahmed; Muhammad M Mirza; Aamer Farooq; Lori Kronish; Mohammad Jahanzeb
Journal:  Breast Cancer (Auckl)       Date:  2010-05-07

Review 9.  Adjuvant therapy of triple negative breast cancer.

Authors:  Edith A Perez; Alvaro Moreno-Aspitia; E Aubrey Thompson; Cathy A Andorfer
Journal:  Breast Cancer Res Treat       Date:  2010-01-22       Impact factor: 4.872

10.  PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Authors:  Ilaria Plantamura; Patrizia Casalini; Erica Dugnani; Marianna Sasso; Elvira D'Ippolito; Monica Tortoreto; Matilde Cacciatore; Carla Guarnotta; Cristina Ghirelli; Isabella Barajon; Francesca Bianchi; Tiziana Triulzi; Roberto Agresti; Andrea Balsari; Manuela Campiglio; Claudio Tripodo; Marilena V Iorio; Elda Tagliabue
Journal:  Mol Oncol       Date:  2014-03-27       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.